BACKGROUND: Body mass index (BMI), waist circumference (WC) and neck circumference (NC) are important screening tools for sleep disordered breathing (SDB); however, the utility of anthropometry for this purpose has not been evaluated among HIV-positive patients. METHODS: HIV-negative men (n=60), HIV-positive men receiving highly active antiretroviral therapy (HIV-positive/HAART; n=58) and HIV-positive men not receiving HAART (HIV-positive/no HAART; n=41) from the Multicenter AIDS Cohort Study underwent a nocturnal sleep study and anthropomorphic assessment. Moderate-severe SDB was defined as an apnea/hypopnea event rate > or =15 episodes/h. Receiver operating characteristic (ROC) curves were used to compare the ability of different anthropometric measurements to predict SDB within each group. RESULTS: Moderate-severe SDB was found in 48% of men (HIV-negative [57%], HIV-positive/HAART [41%] and HIV-positive/no HAART [44%]). The performance of BMI, WC and NC to predict SDB was excellent among the HIV-negative men (ROC areas under the curve [AUCs] 0.83, 0.88 and 0.88, respectively) and fair among the HIV-positive/HAART group (AUC 0.71, 0.77 and 0.77, respectively). By contrast, these measurements had no predictive value in the HIV-positive/no HAART group (AUC 0.43, 0.41 and 0.45, respectively). Moreover, in the HIV-positive/no HAART group, moderate-severe SDB was independently associated with serum C-reactive protein > or =3.0 mg/l (odds ratio 6.9; P=0.04) and HIV RNA>10,000 copies/ml (odds ratio 7.1; P=0.05). CONCLUSIONS: BMI, WC and NC had a better predictive value for moderate-severe SDB in HIV-positive men compared with HIV-positive [corrected] men, and had no value among HIV-positive/no HAART men. Among this latter group, systemic inflammation might contribute to the pathogenesis of SDB.
BACKGROUND: Body mass index (BMI), waist circumference (WC) and neck circumference (NC) are important screening tools for sleep disordered breathing (SDB); however, the utility of anthropometry for this purpose has not been evaluated among HIV-positive patients. METHODS:HIV-negative men (n=60), HIV-positive men receiving highly active antiretroviral therapy (HIV-positive/HAART; n=58) and HIV-positive men not receiving HAART (HIV-positive/no HAART; n=41) from the Multicenter AIDS Cohort Study underwent a nocturnal sleep study and anthropomorphic assessment. Moderate-severe SDB was defined as an apnea/hypopnea event rate > or =15 episodes/h. Receiver operating characteristic (ROC) curves were used to compare the ability of different anthropometric measurements to predict SDB within each group. RESULTS: Moderate-severe SDB was found in 48% of men (HIV-negative [57%], HIV-positive/HAART [41%] and HIV-positive/no HAART [44%]). The performance of BMI, WC and NC to predict SDB was excellent among the HIV-negative men (ROC areas under the curve [AUCs] 0.83, 0.88 and 0.88, respectively) and fair among the HIV-positive/HAART group (AUC 0.71, 0.77 and 0.77, respectively). By contrast, these measurements had no predictive value in the HIV-positive/no HAART group (AUC 0.43, 0.41 and 0.45, respectively). Moreover, in the HIV-positive/no HAART group, moderate-severe SDB was independently associated with serum C-reactive protein > or =3.0 mg/l (odds ratio 6.9; P=0.04) and HIV RNA>10,000 copies/ml (odds ratio 7.1; P=0.05). CONCLUSIONS: BMI, WC and NC had a better predictive value for moderate-severe SDB in HIV-positive men compared with HIV-positive [corrected] men, and had no value among HIV-positive/no HAART men. Among this latter group, systemic inflammation might contribute to the pathogenesis of SDB.
Authors: Frank J Palella; Stephen R Cole; Joan S Chmiel; Sharon A Riddler; Barbara Visscher; Adrian Dobs; Carolyn Williams Journal: Clin Infect Dis Date: 2004-03-01 Impact factor: 9.079
Authors: Todd T Brown; Haitao Chu; Zhaojie Wang; Frank J Palella; Lawrence Kingsley; Mallory D Witt; Adrian S Dobs Journal: AIDS Date: 2007-08-20 Impact factor: 4.177
Authors: Todd T Brown; Xiaoqiang Xu; Majnu John; Jaya Singh; Lawrence A Kingsley; Frank J Palella; Mallory D Witt; Joseph B Margolick; Adrian S Dobs Journal: AIDS Res Ther Date: 2009-05-13 Impact factor: 2.250
Authors: K M Kunisaki; K M Akgün; D A Fiellin; C L Gibert; J W Kim; D Rimland; M C Rodriguez-Barradas; H K Yaggi; K Crothers Journal: HIV Med Date: 2014-09-17 Impact factor: 3.180
Authors: Cecilia M Shikuma; Lindsay Kohorn; Robert Paul; Dominic C Chow; Kalpana J Kallianpur; Maegen Walker; Scott Souza; Louie Mar A Gangcuangco; Beau K Nakamoto; Francis D Pien; Timothy Duerler; Linda Castro; Lorna Nagamine; Bruce Soll Journal: HIV Clin Trials Date: 2018-11-19
Authors: Emily P Brigham; Susheel P Patil; Lisa P Jacobson; Joseph B Margolick; Rebecca Godfrey; Jacquett Johnson; Lisette M Johnson-Hill; Sandra Reynolds; Alan R Schwartz; Philip L Smith; Todd T Brown Journal: Antivir Ther Date: 2014-02-12
Authors: Kathleen V Fitch; Takara L Stanley; Sara E Looby; Alison M Rope; Steven K Grinspoon Journal: Diabetes Care Date: 2011-03-04 Impact factor: 19.112
Authors: Susheel P Patil; Todd T Brown; Lisa P Jacobson; Joseph B Margolick; Alison Laffan; Lisette Johnson-Hill; Rebecca Godfrey; Jacquett Johnson; Sandra Reynolds; Alan R Schwartz; Philip L Smith Journal: PLoS One Date: 2014-07-03 Impact factor: 3.240
Authors: Matthew R Gingo; Goundappa K Balasubramani; Thomas B Rice; Lawrence Kingsley; Eric C Kleerup; Roger Detels; Eric C Seaberg; Ruth M Greenblatt; Susan Holman; Laurence Huang; Sarah H Sutton; Marnie Bertolet; Alison Morris Journal: BMC Pulm Med Date: 2014-04-30 Impact factor: 3.317